Skip to main content
. 2021 Oct 12;22(6):827. doi: 10.3892/ol.2021.13089

Figure 9.

Figure 9.

Schematic diagram of the effects of sorafenib on melanoma cells. Sorafenib inhibited c-Kit, PDGFR, VEGFR, B-Raf and c-Raf activation melanoma cells with c-Kit aberration. This subsequently suppresses tumor growth and metastasis. Therefore, sorafenib may have potential clinical applications for the treatment of metastatic melanoma with c-Kit aberration. VLA, very late antigen; PDGFR, platelet derived growth factor receptor.